However, these new emergent dual agonists need further investigation to understand the mechanisms of action, how to interact with the respective receptors, increase efficacy, and good safety profile [90,91,92,93,94]
Penuel E, Li C, Parab V, Burton L, Cowan KJ, Merchant M, et al
Another recent example of a class I c-MET inhibitor in earlier phases of clinical development is AMG - 337 (Amgen, Thousand Oaks, California, USA), an orally bioavailable highly selective inhibitor of the c-MET receptor with a half maximal inhibitory concentration (IC50) of 1 nM which has reached phase II studies in patients with GI cancer or other MET-amplified solid tumors [112]
Circulatory Health: Health and strength are the words we want to describe our hearts
Understanding your FTO genotype helps your PlexusDx provider select the right GLP-1 compound and dosing strategy to align with your genetic predisposition
Blend Structure Research Areas Cellular Energy & Mitochondrial Function Metabolic Regulation & Obesity Research Muscle Preservation & Physical Performance Neuroprotection & Cognitive Function Longevity & Anti-Aging Mechanisms Preclinical Cancer Research
